LRP1B Deletion in High-Grade Serous Ovarian Cancers Is Associated with Acquired Chemotherapy Resistance to Liposomal Doxorubicin

Prue A Cowin; Joshy George; Sian Fereday; Elizabeth Loehrer; Peter Van Loo; Carleen Cullinane; Dariush Etemadmoghadam; Sarah Ftouni; Laura Galletta; Michael S Anglesio; Joy Hendley; Leanne Bowes; Karen E Sheppard; Elizabeth L Christie; Richard B Pearson; Paul R Harnett; Viola Heinzelmann-Schwarz; Michael Friedlander; Orla McNally; Michael Quinn; Peter Campbell; Anna deFazio; David DL Bowtell

Journal article

LRP1B Deletion in High-Grade Serous Ovarian Cancers Is Associated with Acquired Chemotherapy Resistance to Liposomal Doxorubicin

Prue A Cowin, Joshy George, Sian Fereday, Elizabeth Loehrer, Peter Van Loo, Carleen Cullinane, Dariush Etemadmoghadam, Sarah Ftouni, Laura Galletta, Michael S Anglesio, Joy Hendley, Leanne Bowes, Karen E Sheppard, Elizabeth L Christie, Richard B Pearson, Paul R Harnett, Viola Heinzelmann-Schwarz, Michael Friedlander, Orla McNally, Michael Quinn Show all

CANCER RESEARCH | AMER ASSOC CANCER RESEARCH | Published : 2012

DOI: 10.1158/0008-5472.CAN-12-0203

University of Melbourne Researchers

Richard Pearson Author The Sir Peter MacCallum Department of Oncology

Orla McNally Author Obstetrics and Gynaecology Royal Women's Hospital/Mercy

David Bowtell Author The Sir Peter MacCallum Department of Oncology

Prue Cowin Author Clinical Pathology

Elizabeth Christie Author The Sir Peter MacCallum Department of Oncology

Related Projects (4)

AUSTRALIAN OVARIAN CANCER STUDY (AOCS): A MULTIDISCIPLINARY OVARIAN CANCER RESOURCE FOR THE GENOMICS ERA

Ovarian cancer is relatively uncommon and is histologically very diverse, making it difficult to analyse ovarian cancer at a molecular level..

Molecular Epidemiology of Ovarian Cancer: The Australian Ovarian Cancer Study National Clinical Follow-Up Core

Ovarian cancer is the seventh most common cancer in Australian women and fifth most common cause of cancer death, with approximately 1200 ne..

AUSTRALASIAN BIOSPECIMEN NETWORK-ONCOLOGY

nan

Australian Biospecimen Network-Oncology

Availability of ethically consented, clinically annotated human cancer tissue is a key determinant of the international competitiveness of A..

Grants

Awarded by U.S. Army Medical Research and Materiel Command

Awarded by National Health and Medical Research Council of Australia (NHMRC)

Awarded by NHMRC

Awarded by Worldwide Cancer Research

Funding Acknowledgements

This work has been supported by an Association for International Cancer Research (AICR) grant (P. A. Cowin, D. D. L. Bowtell). AOCS was supported by the U.S. Army Medical Research and Materiel Command under DAMD17-01-1-0729, the National Health and Medical Research Council of Australia (NHMRC, 400281 & 400413), Cancer Council Victoria, Cancer Council Queensland, Cancer Council New South Wales, Cancer Council South Australia, The Cancer Foundation of Western Australia and Cancer Council Tasmania. The Australasian Biospecimens Network-Oncology was funded by NHMRC (310670 & 628903). P. V. Loo is a postdoctoral researcher of the Research Foundation-Flanders (FWO).